10-Q: Phathom Pharmaceuticals Q3 2025: Revenue Soars, Losses Narrow

Phathom Pharmaceuticals reports significant revenue growth and a reduced net loss in Q3 2025, driven by strong VOQUEZNA sales, while managing liquidity and strategic restructuring.

Summary

• Product revenue for the three months ended September 30, 2025, was $49.5 million, a substantial increase from $16.4 million in the same period of 2024.
• Net loss for Q3 2025 significantly decreased to $(29.973) million, compared to $(85.577) million in Q3 2024.
• For the nine months ended September 30, 2025, product revenue reached $117.5 million, up from $25.6 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, was $(200.099) million, an improvement from $(259.875) million in the same period of 2024.
• Cash and cash equivalents totaled $135.2 million as of September 30, 2025, down from $297.3 million at December 31, 2024.
• An organizational restructuring plan in May 2025 reduced the workforce by 26 employees (approximately 6%) and incurred $9.2 million in charges.
• The FDA approved VOQUEZNA 10 mg tablets for the relief of heartburn associated with Non-Erosive GERD on July 17, 2024.
• The Orange Book listing for VOQUEZNA tablets was updated on June 16, 2025, to reflect a full ten-year New Chemical Entity (NCE) exclusivity period through May 3, 2032.
• Over 790,000 prescriptions for VOQUEZNA products have been filled since launch, written by more than 34,100 prescribers, as of October 17, 2025.
• Commercial coverage for VOQUEZNA extends to over 80% of total U.S. commercial lives.
• Sanjeev Narula was appointed Chief Financial and Business Officer, effective October 6, 2025.

Sentiment

Score: 7

Explanation: The company shows strong revenue growth and a significant reduction in net loss, driven by successful product launches and FDA approvals. However, it continues to operate at a net loss and negative cash flow, indicating ongoing financial challenges and reliance on future funding. Strategic restructuring and NCE exclusivity extension are positive, but the inability to draw further debt tranches highlights continued capital needs.

Positives

• Product revenue increased by 202% to $49.5 million in Q3 2025 from $16.4 million in Q3 2024, demonstrating strong commercial momentum.
• Net loss decreased by 65% to $(29.973) million in Q3 2025 from $(85.577) million in Q3 2024, indicating improved operational efficiency.
• FDA approval of VOQUEZNA 10 mg tablets for Non-Erosive GERD on July 17, 2024, expands the product's market potential into the largest GERD category.
• New Chemical Entity (NCE) exclusivity for VOQUEZNA tablets was extended through May 3, 2032, providing a longer period of market protection.
• The commercial launch of VOQUEZNA products shows strong physician and patient demand, with over 790,000 prescriptions filled since launch.
• Broad commercial coverage for VOQUEZNA, reaching over 80% of total U.S. commercial lives, supports continued sales growth.
• Implementation of a cost reduction and organizational restructuring plan in May 2025 is designed to reduce cash burn and focus resources on commercial execution.

Negatives

• Continued to incur significant net losses, with an accumulated deficit of $1.5 billion as of September 30, 2025.
• Experienced negative cash flows from operating activities, totaling $(161.8) million for the nine months ended September 30, 2025.
• Cash and cash equivalents decreased by $162.1 million from December 31, 2024, to September 30, 2025, highlighting ongoing cash utilization.
• Does not expect to meet the revenue threshold to draw the Sixth Tranche of the Hercules Loan Agreement, indicating a potential constraint on future debt funding.
• No additional funding is available under the Revenue Interest Financing Agreement as of September 30, 2025.

Risks

• Uncertainty regarding the ability to achieve and sustain profitability, as net losses and negative cash flows from operations have been incurred since inception.
• Reliance on future equity offerings, additional debt financings, or other capital sources, including potential collaborations, to fund ongoing cash needs.
• Risk of being unable to raise additional funds on favorable terms or at all, which could be exacerbated by global economic conditions.
• Potential for supply disruption of clarithromycin tablets, a component of VOQUEZNA TRIPLE PAK, which represents approximately 1% of total revenue, leading to an inability to commercialize the product.
• Forecasts of financial resources and operating plans involve inherent risks and uncertainties, and capital resources could deplete sooner than expected.
• The costly and unpredictable nature of clinical trials means the timing of progress and expenses for current or future product candidates is uncertain.
• Future capital raises through equity or convertible debt securities could dilute the ownership interest of existing stockholders.
• Debt financing agreements may contain covenants that limit or restrict the company's ability to take specific actions, such as incurring additional debt or declaring dividends.
• Raising funds through collaborations or similar arrangements may require relinquishing valuable rights to technologies, future revenue streams, or product candidates.

Future Outlook

Management expects to continue incurring net losses for the foreseeable future. Existing cash and cash equivalents, combined with anticipated product revenues, are believed to be sufficient to fund operations for at least the next twelve months. The company plans to evaluate potential commercial partnerships for vonoprazan in Europe and Canada, explore development into other indications, dosing regimens, and alternative formulations, and consider in-licensing or acquiring additional clinical or commercial stage product candidates for GI diseases in a capital-efficient manner. The company does not anticipate meeting the revenue threshold to draw the Sixth Tranche of the Hercules Loan Agreement and does not expect to need additional amounts under this agreement.

Management Comments

• Commercial launch for VOQUEZNA in the U.S. for both the Erosive GERD and H. pylori indications, and VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for treatment of H. pylori infection initiated in the fourth quarter of 2023.
• Commercial launch for VOQUEZNA continues to build momentum, and launch data shows strong physician and patient demand.
• As of October 17, 2025, over 790,000 prescriptions for VOQUEZNA tablets, VOQUEZNA Triple Pak, and VOQUEZNA Dual Pak have been filled since launch, written by more than 34,100 prescribers.
• Broad commercial coverage for VOQUEZNA is maintained, with over 120 million, or over 80%, of total U.S. commercial lives having access to VOQUEZNA tablets.
• Based on the current operating plan, existing cash and cash equivalents, together with anticipated product revenues, are believed to be sufficient to fund operations for at least the next twelve months.
• Based on current revenue projections, the company does not expect to meet the revenue threshold to draw the Sixth Tranche of the Hercules Loan Agreement, and the current operating plan does not anticipate a need to draw any additional amounts under the Loan Agreement.

Industry Context

Vonoprazan, the active ingredient in VOQUEZNA products, represents a novel class of medicines (potassium-competitive acid blockers or PCABs) that block acid secretion. It is the first gastric anti-secretory agent from this class approved in the U.S., Europe, or Canada in over 30 years, positioning it as a significant innovation in the treatment of gastrointestinal diseases. This innovation offers rapid, potent, and durable anti-secretory effects, demonstrating clinical benefits over the current standard of care for Erosive GERD and H. pylori infection. The company's strategic focus on GI diseases and efforts to expand commercial reach through potential partnerships in Europe and Canada align with broader industry trends of specialized therapeutic development and global market penetration.

Comparison to Industry Standards

• Vonoprazan, developed by Takeda, generated peak net sales of approximately $850 million in Japan, indicating a strong market potential for the drug globally and providing a benchmark for its commercial success.
• VOQUEZNA is the first gastric anti-secretory agent from a novel class (PCABs) approved in the U.S., Europe, or Canada in over 30 years, highlighting its innovative position compared to established treatments in the GI disease market.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any material legal proceedings. May be involved in legal proceedings or subject to claims incident to the ordinary course of business from time to time.

Related Party Transactions

• Frazier Life Sciences IX, L.P., a significant stockholder and affiliate of Dr. James Topper (Board of Directors), participated in the August 2024 underwritten public offering by purchasing pre-funded warrants on the same terms as all other investors.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity offerings; benefits from NCE exclusivity extension and strong product launch performance; impact from stock-based compensation plans.
• Employees: Workforce reduction of 26 employees (6%) due to restructuring in May 2025, incurring $9.2 million in charges, indicating a focus on cost efficiency.
• Customers: Continued availability of VOQUEZNA products, including the new approval for Non-Erosive GERD, enhancing treatment options. Potential, though currently not anticipated, risk of disruption for VOQUEZNA TRIPLE PAK due to clarithromycin supply.
• Creditors: The company is in compliance with all applicable covenants under the Loan Agreement as of September 30, 2025. However, the decision not to draw further tranches of the Hercules loan suggests a cautious approach to debt and potential future reliance on other funding sources.

Next Steps

• Evaluate potential for commercial partnerships for vonoprazan in Europe and Canada.
• Evaluate potential development of vonoprazan into other indications, dosing regimens, and alternative formulations and packaging.
• Evaluate the in-license or acquisition of additional clinical or commercial stage product candidates for GI diseases in a capital-efficient manner.
• Continue the Phase 2 clinical trial of vonoprazan in eosinophilic esophagitis (EoE).
• Actively monitor the Sandoz supply situation for clarithromycin tablets to determine if a supply disruption may arise in the future.

Key Dates

Recommendation

Phathom Pharmaceuticals demonstrates strong revenue growth and a narrowing net loss, driven by successful product launches and expanded FDA approvals for VOQUEZNA. The extension of NCE exclusivity is a significant positive for long-term market protection. However, the company continues to incur substantial net losses and negative operating cash flow, indicating ongoing financial challenges and a reliance on future capital raises. While management believes existing cash and anticipated revenues are sufficient for the next 12 months, the inability to meet revenue thresholds for additional debt tranches suggests a cautious outlook on funding. The restructuring plan is a positive step towards cost control. Given the strong product performance but persistent financial burn and capital needs, a 'hold' recommendation is appropriate, awaiting further evidence of sustained profitability and reduced reliance on external financing.

Keywords

Phathom Pharmaceuticals, PHAT, VOQUEZNA, vonoprazan, GERD, Erosive GERD, Non-Erosive GERD, H. pylori, biopharmaceutical, Q3 2025 earnings, SEC 10-Q, financial results, drug approval, NCE exclusivity, gastrointestinal diseases, pharmaceutical, stock